key: cord-0874127-e44535dz
authors: Kanatas, A.; Hart, P.; Mücke, T.
title: Hypercoagulability following COVID-19 infection: at what stage is it safe to do a free flap?
date: 2020-08-20
journal: Br J Oral Maxillofac Surg
DOI: 10.1016/j.bjoms.2020.08.092
sha: 5ebdfe798495309f9db32d14f2c08b54d59133c5
doc_id: 874127
cord_uid: e44535dz

nan

crisis is affecting the management of head and neck cancer (HNC) patients. Clinicians worldwide face this new severe infectious lung disease with limited therapies. In some units the service of head and neck cancer-related surgery has been cancelled or at least delayed.

The demand for maintaining intensive care unit (ICU) availability has affected surgeries with reconstruction, when free tissue transfer is required. Protocols and guidance regarding the management of cancer have been published by the relevant associations 3,4 . As part of the preoperative investigations, antigen / PCR test has been added for all head and neck cancer patients due to the increased risk of morbidity and mortality to both patients and clinicians.

Health systems around the world are gradually starting to have empty ICU beds and clinicians will soon start to think about free tissue transfer operations for suitable patients.

COVID-19 disease is now so widespread that some patients will have tested positive before their surgical intervention. Inevitably, their operation will be cancelled and be re-scheduled in asymptomatic individuals, and the use of D-dimer to predict risk of recurrent VTE after stopping anticoagulation following a VTE 10, 11 . Therefore D-dimer may yet have a role predicting risk of thrombotic events in free flap patients. In those cases where the D-dimer is elevated, extensive surgery may need to be delayed or the reconstruction modified, although at present more work is required to identify a numerical cut-off. Regarding prophylactic anticoagulation for either microvascular or venous thrombosis, existing protocols relating to the management of thromboembolic complications of COVID-19 do not address the patients undergoing free flap transfer 12 . Further data is therefore required in order to assess the need of the type of drug, dosage and optimal duration of prophylaxis.

At present we don't have robust data in order to make recommendations. Every patient needing reconstruction with a free flap, requires careful assessment by the clinical team. In addition to the haematological testing, patient counselling and initiation of deep venous thromboembolism prophylaxis measures are critical clinical components of care. The clinical team needs to reassess the patients' performance status following COVID-19. Whilst most people recover from pneumonia without any lasting lung damage, the pneumonia associated with COVID-19, in certain patients, causes lung injury with breathing difficulties J o u r n a l P r e -p r o o f

A novel coronavirus from patients with pneumonia in China

Emerging understandings of 2019-nCoV

Hypercoagulability of COVID-19 patients in Intensive Care Unit. A Report of Thromboelastography Findings and other Parameters of Hemostasis

Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study

D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19

Hematological findings and complications of COVID-19

Clinical characteristics of 24 asymptomatic infections with COVID-19 screened contacts in Nanjing, China. Science China Life Sciences

Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism

Prospective study of plasma D-dimer and incident venous thromboembolism: The Atherosclerosis Risk in Communities (ARIC) Study. Thrombosis research

Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands

The authors have no conflict of interest to report J o u r n a l P r e -p r o o f